ArticleVaccine2023
Vaccine value profile for cytomegalovirus.
Article in Vaccine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Human herpesvirus evasion of humoral immunity and implications for vaccine development.Nature reviews. Microbiology · 2026Review
- The Current Status ofPathogens (Basel, Switzerland) · 2026Article
- Investigating the Role of Cytomegalovirus as a Cause of Stillbirths and Child Deaths in Low- and Middle-Income Countries Through Postmortem Minimally Invasive Tissue Sampling.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Cytomegalovirus seroprevalence and seroconversion in the Irish blood donor population.Epidemiology and infection · 2026Article
- Using Artificial Intelligence Methods to Evaluate the Effect of the National Cytomegalovirus Awareness Month on the Content and Sentiment of Social Media Posts: Infodemiology Study.JMIR infodemiology · 2026Article
- Birth prevalence, clinical sequelae, and management of congenital cytomegalovirus infections in Australia, 1999-2023: a national prospective study.The Medical journal of Australia · 2025Observational
- Advancements and potential in the prevention of congenital CMV infection.Seminars in fetal & neonatal medicine · 2025Review
- Risk factors for unnatural mortality in persons with serious mental illness.Scientific reports · 2025Article
- Current status of primary, secondary and tertiary prevention of congenital cytomegalovirus disease: a call to action.Current opinion in infectious diseases · 2025Review
- Cytomegalovirus Seroprevalence in Northern Poland in the Population Planning Pregnancy and Pregnant Women.Viruses · 2025Article
- Determination of whole genome sequence of human cytomegalovirus circulating in Japan and discovery of geographic genome structure in UL148 gene.Virus research · 2025Article
- Auditory and Vestibular Involvement in Congenital Cytomegalovirus Infection.Pathogens (Basel, Switzerland) · 2024Review
- "I try to take all the time needed, even if i do not have it!": Knowledge, attitudes, practices of perinatal care providers in canada about vaccination.Vaccine: X · 2024Article
- Human Cytomegalovirus Infection and Neurocognitive and Neuropsychiatric Health.Pathogens (Basel, Switzerland) · 2024Review
- The Full Value of Vaccine Assessments Concept-Current Opportunities and Recommendations.Vaccines · 2024Article
- Cytomegalovirus Infection: Concern for Occupational, Environmental, and Nosocomial Infections?Indian journal of occupational and environmental medicineArticle
- CMV-induced Hearing Loss.Newborn (Clarksville, Md.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 8 institutions in 6 countries.
Funding
Abstract
Cytomegalovirus (CMV) is the most common infectious cause of congenital malformation and a leading cause of developmental disabilities such as sensorineural hearing loss (SNHL), motor and cognitive deficits. The significant disease burden from congenital CMV infection (cCMV) led the US National Institute of Medicine to rank CMV vaccine development as the highest priority. An average of 6.7/1000 live births are affected by cCMV, but the prevalence varies across and within countries. In contrast to other congenital infections such as rubella and toxoplasmosis, the prevalence of cCMV increases with CMV seroprevalence rates in the population. The true global burden of cCMV disease is likely underestimated because most infected infants (85-90 %) have asymptomatic infection and are not identified. However, about 7-11 % of those with asymptomatic infection will develop SNHL throughout early childhood. Although no licensed CMV vaccine exists, several candidate vaccines are in development, including one currently in phase 3 trials. Licensure of one or more vaccine candidates is feasible within the next five years. Various models of CMV vaccine strategies employing different target populations have shown to provide substantial benefit in reducing cCMV. Although CMV can cause end-organ disease with significant morbidity and mortality in immunocompromised individuals, the focus of this vaccine value profile (VVP) is on preventing or reducing the cCMV disease burden. This CMV VVP provides a high-level, comprehensive assessment of the currently available data to inform the potential public health, economic, and societal value of CMV vaccines. The CMV VVP was developed by a working group of subject matter experts from academia, public health groups, policy organizations, and non-profit organizations. All contributors have extensive expertise on various elements of the CMV VVP and have described the state of knowledge and identified the current gaps. The VVP was developed using only existing and publicly available information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.